iBio to Report Fiscal 2022 Third Quarter Economic Success and Present Corporate Update on Thursday, Could 12, 2022

iBio, Inc.

iBio, Inc.

BRYAN, Texas, May well 05, 2022 (World NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of future-generation biopharmaceuticals and pioneer of the sustainable, plant-centered FastPharming Producing Program®, introduced today that it will report its fiscal 2022 3rd quarter fiscal final results soon after market shut on Thursday, Might 12, 2022. iBio administration will host a webcast and meeting call at 4:30 p.m. Jap Time to discuss the final results and supply a corporate update.

The stay and archived webcast may be accessed on the Company’s site at www.ibioinc.com below “News and Events” in the Investors portion. The reside phone can be accessed by dialing (833) 672-0651 (domestic) or (929) 517-0227 (worldwide) and referencing meeting ID: 2392536.

About iBio, Inc.

iBio is a developer of upcoming-generation biopharmaceuticals and a pioneer in sustainable, plant-dependent biologics manufacturing. Its FastPharming Technique® brings together vertical farming, automatic hydroponics, and novel glycosylation systems to quickly supply significant-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is acquiring proprietary biopharmaceuticals for the treatment of cancers, as very well as fibrotic and infectious conditions. The Company’s wholly-owned subsidiary, iBio CDMO LLC, gives FastPharming Agreement Improvement and Producing Services alongside with Glycaneering Development Services™ for superior recombinant protein layout. For much more details, take a look at www.ibioinc.com.


Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580

iBio Inc

Resource backlink

You May Also Like